They must clearly distinguish their products from gray-market manufacturers caught in the FDA’s crosshairs.

While consumers trust doctors, they increasingly rely on AI and influencers for wellness advice, making misinformation more accessible and elevating the value of physician-backed brand content.

Novo Nordisk’s oral obesity treatment is set for a private-pay debut in the UK as drugmakers look to broaden GLP-1 adoption beyond injections.

Consumers are treating health and wellness as essential spending even in a tough economy. Social media and wellness culture are fueling demand for supplements, healthier food, and longevity products. At the same time, misinformation and pressure to stay healthy are increasing.

Reduced employer coverage of weight loss drugs could push patients to cash-pay options or off treatment, increasing pressure on pharma companies to lower prices.

Ad watchdog sides with pharma over misleading GLP-1 microdose telehealth marketing—but this scrutiny won't impact sales thanks to high consumer demand.

Its roughly 30% average weight loss could expand options and accelerate a tiered treatment market ranging from oral pill convenience to surgical intervention for those with severe obesity.

Nourish's fresh capital fuels its model that combines GLP-1 drugs with health coaching—an emerging trend as insurers and employers demand proof that digital care reduces wasteful spending.

Pharma execs detail strategies for gov’t pricing deals, countering vaccine skepticism, and driving D2C sales at FT’s US Pharma and Biotech Summit.

Telehealth firms switching from compounded to brand-name GLP-1s must offer stronger patient support and expand into other high-demand treatments, like hormone therapies.

The move could curb telehealth’s copycat obesity drugs and steer patients back to branded options.

Amazon aims to turn GLP-1 demand into a funnel for One Medical, though limiting new prescriptions to members softens the competitive threat to other telehealth players.

Younger consumers respond to GLP-1 ads, but increasing ad spend risks fatigue, making sharper creative and more point-of-care marketing increasingly important.

Backlash over Medvi’s telehealth business after a NYT report signals increasing scrutiny of online health ads.

Rapid share gains in India come at the expense of branded drugs, challenging premium pricing models and raising the bar for new entrants.

Wellness culture drives increased consumer health spending, but brands still must avoid shame-based messaging that undermines trust.

The stage is set for a market share battle over efficacy, convenience, and brand recognition.

The move signals a consumer marketing strategy shift as GLP-1 drugs demand loyalty, engagement, and experience beyond clinical outcomes.

Healthcare and pharma brands must adapt digital marketing for the AI search era, make CTV actionable for older viewers, and align social strategies with how consumers discover health content.

Lilly’s new safety allegations add fuel to lawsuits and FDA actions targeting telehealth sellers of compounded weight loss drugs.